cediranib (AZD2171)

vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor

Also Known As:

AZD2171; 4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline; 4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline (2Z)-but-2-enedioate; 4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline (2Z)-but-2-enedioate (1:1); AZD 2171; AZD-2171; AZD-2171 maleate; AZD2171 maleate; Recentin; cediranib maleate

Networked: 254 relevant articles (46 outcomes, 132 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinazolines: 402
      - cediranib: 254
    - Indoles: 200
      - cediranib: 254

Experts

1.	Batchelor, Tracy T: 18 articles (01/2017 - 01/2007)
2.	Jain, Rakesh K: 18 articles (04/2016 - 01/2007)
3.	Jürgensmeier, Juliane M: 17 articles (07/2014 - 05/2005)
4.	Ivy, S Percy: 13 articles (01/2021 - 08/2010)
5.	Wen, Patrick Y: 11 articles (01/2017 - 01/2007)
6.	Sorensen, A Gregory: 11 articles (01/2014 - 01/2007)
7.	Duda, Dan G: 10 articles (01/2017 - 01/2007)
8.	Ivy, Percy: 7 articles (01/2022 - 01/2007)
9.	Kohn, Elise C: 7 articles (01/2022 - 10/2014)
10.	Matulonis, Ursula A: 7 articles (01/2022 - 11/2009)

Related Diseases

1.	Neoplasms (Cancer) 12/01/2009 - "Cediranib treatment (8 and 12 days) led to a significant reduction in tumor size (42-50%) and a highly significant reduction in MVD (30-55%) versus controls. " 08/01/2007 - "This effect preceded a significant reduction in tumor microvessel density, which was detectable following 52 h of AZD2171 treatment. " 01/01/2018 - "Population exposure-safety analysis of cediranib for Phase I and II studies in patients with cancer." 01/01/2017 - "Plasma concentrations and covariates from 625 cancer patients after single or multiple oral cediranib administrations ranging from 0.5 to 90 mg in 19 Phase I and II studies were included in the analysis. " 02/01/2013 - "No change between the pre- and post-treatment tumor apparent diffusion coefficients in either the cediranib- or vehicle-treated group was observed over the course of this study. "
2.	Glioblastoma (Glioblastoma Multiforme) 08/01/2015 - "Collectively, our results provide pre-clinical evidence for the potential of PLGA formulations of AZD2171 and sTRAIL to serve as an effective treatment for glioblastoma." 01/01/2023 - "NRG/RTOG 0837: Randomized, phase II, double-blind, placebo-controlled trial of chemoradiation with or without cediranib in newly diagnosed glioblastoma." 06/10/2010 - "We performed a phase II study of cediranib in patients with recurrent glioblastoma. " 08/01/2015 - "AZD2171 released from PLGA-MS was at least effective as the free drug in inhibiting endothelial growth and proliferation (in vitro), and, surprisingly, had a profound cytotoxic effect also towards in vitro cultured glioblastoma cell-lines (U87 and A172). " 01/01/2014 - "Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation."
3.	Ovarian Neoplasms (Ovarian Cancer) 03/01/2016 - "The aim of this manuscript is to review the current role of cediranib in the treatment of ovarian cancer and to present an overview of the ongoing clinical trials in this setting. " 01/01/2022 - "Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer." 01/01/2021 - "The relative reduction in the risk of death of 14% risk of death was not conventionally statistically significant, but this improvement and the increase in the mean survival time in this analysis suggest that cediranib may have worthwhile activity in the treatment of recurrent ovarian cancer and that further research should be undertaken." 10/01/2017 - "The role of Cediranib in ovarian cancer." 07/15/2017 - "Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial."
4.	Colorectal Neoplasms (Colorectal Cancer) 10/10/2012 - "Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II)." 08/01/2012 - "Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer." 04/01/2012 - "Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: results from the randomised phase II part of a phase I/II study." 02/15/2009 - "Purposes of this study were to determine the recommended phase II dose of cediranib in combination with standard doses of modified FOLFOX-6 (mFOLFOX-6), and the tolerability, safety, pharmacokinetics, and antitumor activity of this combination in patients with untreated metastatic colorectal cancer. " 07/01/2013 - "KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib."
5.	Glioma (Gliomas) 01/01/2015 - "Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma." 05/01/2012 - "These findings are clinically relevant to the efficacy of cediranib chemotherapy in glioma." 08/01/2015 - "This improved effect, compared to other therapeutic approaches involving AZD2171, was shown to affect both tumor vasculature and the glioma cells. " 07/01/2013 - "In the U87 intracerebral glioma model, within the first day of administration of cediranib, the intratumoral concentrations of TMZ in tumor ECF were slightly, but not statistically significantly, increased when compared to the treatment of TMZ alone with radiographic evidence of a normalized BBB." 01/01/2014 - "Our results provide compelling evidence that autophagic vacuole accumulation plays a causal role in the anti-glioma cytotoxic efficacy of combined cediranib/quinacrine. "

Related Drugs and Biologics

1.	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
2.	cediranib (AZD2171)
3.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
4.	Tyrosine Kinase Inhibitors
5.	Platinum
6.	Bevacizumab (Avastin)
7.	olaparib
8.	Sunitinib (Sutent)
9.	Lomustine (CCNU)
10.	Paclitaxel (Taxol)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Radiotherapy
4.	Castration
5.	Chemoradiotherapy